| Q40055597 | A role for altered microtubule polymer levels in vincristine resistance of childhood acute lymphoblastic leukemia xenografts. |
| Q35953902 | A systematic evaluation of the safety and toxicity of fingolimod for its potential use in the treatment of acute myeloid leukaemia. |
| Q38798804 | Activating protein phosphatase 2A (PP2A) enhances tristetraprolin (TTP) anti-inflammatory function in A549 lung epithelial cells. |
| Q40859498 | Activation of protein phosphatase 2A in FLT3+ acute myeloid leukemia cells enhances the cytotoxicity of FLT3 tyrosine kinase inhibitors. |
| Q34044305 | Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons. |
| Q40223909 | Alterations in gamma-actin and tubulin-targeted drug resistance in childhood leukemia |
| Q35617207 | Basal protein phosphatase 2A activity restrains cytokine expression: role for MAPKs and tristetraprolin |
| Q52687488 | Cell-Free DNA Blood Collection Tubes Are Appropriate for Clinical Proteomics: A Demonstration in Colorectal Cancer. |
| Q35053674 | Clinical proteomics: present and future prospects. |
| Q91967501 | Comment on "PP2A inhibition sensitizes cancer stem cells to ABL tyrosine kinase inhibitors in BCR-ABL human leukemia" |
| Q37837372 | Controlling the cell cycle: the role of calcium/calmodulin-stimulated protein kinases I and II. |
| Q39035851 | Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition. |
| Q89273978 | Development of novel PP2A activators for use in the treatment of acute myeloid leukaemia |
| Q35180685 | Drug resistance mechanisms in cancer cells: a proteomics perspective. |
| Q34104555 | Essential requirement for PP2A inhibition by the oncogenic receptor c-KIT suggests PP2A reactivation as a strategy to treat c-KIT+ cancers |
| Q34800588 | Essential role of protein phosphatase 2A in metaphase II arrest and activation of mouse eggs shown by okadaic acid, dominant negative protein phosphatase 2A, and FTY720. |
| Q37635795 | Expression of renin-angiotensin system (RAS) components in endometrial cancer |
| Q35945171 | FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia |
| Q47571869 | Functional importance of PP2A regulatory subunit loss in breast cancer |
| Q39175714 | Harnessing the power of proteomics for identification of oncogenic, druggable signalling pathways in cancer |
| Q33864443 | Identification of novel diagnostic biomarkers for asthma and chronic obstructive pulmonary disease. |
| Q36126732 | Improving the targeting of tubulin-binding agents: lessons from drug resistance studies. |
| Q38943724 | Involvement of vacuolar H(+)-ATPase in killing of human melanoma cells by the sphingosine kinase analogue FTY720. |
| Q38602949 | Mutant JAK3 phosphoproteomic profiling predicts synergism between JAK3 inhibitors and MEK/BCL2 inhibitors for the treatment of T-cell acute lymphoblastic leukemia. |
| Q80564109 | Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs |
| Q28252483 | PP2A phosphatase suppresses function of the mesenchymal invasion regulator NEDD9 |
| Q86869643 | PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity |
| Q39015110 | PR55α-containing protein phosphatase 2A complexes promote cancer cell migration and invasion through regulation of AP-1 transcriptional activity. |
| Q42503019 | Peripheral Lipopolysaccharide Challenge Induces Long-Term Changes in Tyrosine Hydroxylase Regulation in the Adrenal Medulla. |
| Q90777632 | Protein phosphatase 2A (PP2A): a key phosphatase in the progression of chronic obstructive pulmonary disease (COPD) to lung cancer |
| Q39670772 | Protein phosphatase 2A carboxymethylation and regulatory B subunits differentially regulate mast cell degranulation |
| Q31155409 | Proteome analysis of vinca alkaloid response and resistance in acute lymphoblastic leukemia reveals novel cytoskeletal alterations. |
| Q33233029 | Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia--an in vivo study. |
| Q100694578 | Quantitative phosphoproteomics uncovers synergy between DNA-PK and FLT3 inhibitors in acute myeloid leukaemia |
| Q39754072 | Regulation of CaMKII by phospho-Thr253 or phospho-Thr286 sensitive targeting alters cellular function. |
| Q39214279 | Salmeterol attenuates chemotactic responses in rhinovirus-induced exacerbation of allergic airways disease by modulating protein phosphatase 2A. |
| Q38835919 | TLR2 ligation induces corticosteroid insensitivity in A549 lung epithelial cells: Anti-inflammatory impact of PP2A activators. |
| Q58555667 | Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance |
| Q48098911 | Targeting PP2A and proteasome activity ameliorates features of allergic airway disease in mice |
| Q43851423 | The E3 ubiquitin ligase midline 1 promotes allergen and rhinovirus-induced asthma by inhibiting protein phosphatase 2A activity. |
| Q73304660 | The microbial proteome database--an automated laboratory catalogue for monitoring protein expression in bacteria |
| Q37416615 | The phosphorylated form of FTY720 activates PP2A, represses inflammation and is devoid of S1P agonism in A549 lung epithelial cells |
| Q74113117 | The proteomics of ageing |
| Q51573670 | Theophylline Represses IL-8 Secretion from Airway Smooth Muscle Cells Independently of Phosphodiesterase Inhibition. Novel Role as a Protein Phosphatase 2A Activator. |
| Q33731727 | Treatment of inflammatory arthritis via targeting of tristetraprolin, a master regulator of pro-inflammatory gene expression |